The SpaceX cargo Dragon, whose sunrise launch painted a glowing "jellyfish" over the eastern United States, docked at the International Space Station at 10:27 a.m. EDT on Oct. 15, according to Space.com. Inside were more than 6,300 pounds (2,860 kilograms) of supplies and research, including experiments that use weightlessness to build artificial retinas and grow miniature human brain tissue.

The medical experiments target conditions that touch millions of American families. One aims to produce implants that could restore some vision to people blinded by retinal disease. Others use lab-grown brain models to study inflammation linked to Alzheimer's, Parkinson's, and multiple sclerosis.

That makes this delivery more than a routine resupply run — it is also early-stage research, and none of these experiments will produce a treatment patients can use anytime soon.

Update Note: This article reports new information involving the SpaceX CRS-35 resupply mission's arrival and its medical research cargo following Nature World News' earlier coverage. The latest verified information comes from Space.com's Oct. 15, 2026, docking report and NASA's mission release, which says Dragon will leave the station in mid-November.

Since the Jellyfish Lit Up the Morning Sky

Nature World News previously reported that the Oct. 13 launch created a "space jellyfish" that one viewer mistook for a comet. The effect appears near sunrise or sunset, when the ground is still dark, but sunlight strikes the rocket's exhaust high overhead. In the thin upper air, the plume expands into a broad, glowing shape, as NASA's launch photo of the 6:33 a.m. EDT liftoff from Cape Canaveral shows.

What has changed since is that the spacecraft arrived safely, docking at the station's Harmony module two days later. NASA astronaut Anil Menon monitored the approach. Dragon also carried the final pair of upgraded roll-out solar arrays, which astronauts plan to install on future spacewalks to boost the station's power.

Growing a Retina Without Gravity

Connecticut biotech company LambdaVision is testing a way to build an artificial retina from hundreds of thin layers of a light-sensitive protein. On Earth, gravity makes those layers settle unevenly, wasting material and limiting quality. In orbit, the layers can form more evenly.

As of June, the company had run nine investigations on the station over the past decade, according to the ISS National Laboratory. It reports that space-made retinas showed better uniformity, optical performance, and stability than Earth-made versions. Those results come from the company and its partners, not independent clinical testing.

The target diseases are age-related macular degeneration and retinitis pigmentosa, which the ISS National Laboratory says affect more than 200 million people worldwide and have no cure. CEO Nicole Wagner has said the work is about "demonstrating the value of manufacturing in space." The next goal is producing more retinas per flight.

Mini-Brains in Orbit and Their Limits

Two brain-tissue projects are also on the station. The National Stem Cell Foundation is growing brain organoids, pea-sized clusters of human brain cells made from stem cells, from patients with Parkinson's disease, primary progressive multiple sclerosis, and Alzheimer's. The team will compare how organoids from people of different genetic backgrounds develop neuroinflammation, a hallmark of those diseases. NSCF CEO Paula Grisanti said, "Our goal is to develop discoveries that benefit patients worldwide," in a foundation release. The foundation says earlier flights found brain organoids mature faster in space.

Researchers at Mount Sinai in New York sent a separate brain model containing neurons, support cells, and tiny blood vessels. It will test how microgravity and space radiation affect the blood-brain barrier and inflammation, and how the APOE4 gene variant, the strongest genetic risk factor for late-onset Alzheimer's, changes those responses, according to HIT Consultant. Mount Sinai also flew beating heart organoids on chips.

These are laboratory models, not patients — organoids lack the full structure of a human brain, and faster aging in space is a research tool, not a cure. Results will take months to analyze after samples return, and any drug ideas would still need years of testing.

Heart Tissue, Glass and a Power Upgrade

The medical cargo did not stop at the brain and eye. A study called Stellar Spheroids is growing 3D human heart tissue models to see whether microgravity produces more advanced blood vessel networks, which could make lab models more realistic for drug testing, according to NASASpaceFlight.com. Mount Sinai's heart chips hold up to 16 beating organoids grown from healthy stem cells to track how heart muscle weakens and blood vessels stiffen in weightlessness.

A materials experiment will form glass from unusual elements while it floats, with solid samples returning to Earth. Researchers hope it leads to stronger, more durable glass for spacecraft and other uses.

The largest items aboard were the last two of eight upgraded roll-out solar arrays. Six are already installed, and the final pair is expected to add roughly 20% to 30% more power as the station's original arrays age. More power means more room for experiments like the ones on this flight.

For families living with these diseases, the practical advice is unchanged. Treatment decisions belong with your doctor, and clinical trials listed through official registries remain the route to new therapies. Be wary of products marketed with claims tied to "space research."

Dragon is scheduled to leave the station in mid-November and splash down off California with time-critical samples. The bottom line is that the jellyfish launch delivered promising medical experiments that will add data on vision loss and brain disease, but meaningful results are months away, and treatments are years away.

What Readers Want to Know

Did the CRS-35 Dragon reach the space station?

Yes. It docked at the Harmony module at 10:27 a.m. EDT on Oct. 15, according to Space.com.

What caused the jellyfish in the sky?

Sunlight hit the rocket's exhaust high in the atmosphere while the ground was still dark, making the expanding plume glow.

What is the artificial retina experiment?

LambdaVision is building retinas from layers of a light-sensitive protein in microgravity, aiming to help people with retinal diseases.

What are brain organoids?

They are small clusters of human brain cells grown from stem cells and used to study disease in the lab.

Will these experiments lead to treatments soon?

No. They are early-stage research, and any treatment would need years of further testing and approval.

When will the experiments come back?

NASA says Dragon will leave the station in mid-November and splash down off California with time-critical samples.